Advanced search
Publication Cover
Cancer Management and Research Volume 14, 2022 - Issue
Submit an article Journal homepage
204
Views
3
CrossRef citations to date
0
Altmetric
Review

Clinical Evaluation of Avelumab in the Treatment of Advanced Urothelial Carcinoma: Focus on Patient Selection and Outcomes

Jennifer E Ten Eyck1 Department of Urology, College of Medicine and Life Sciences, The University of Toledo, Toledo, OH, USAORCID Iconhttps://orcid.org/0000-0002-5504-8672
ORCID Icon,
Navkirat Kahlon2 Department of Hematology Oncology, College of Medicine and Life Sciences, The University of Toledo, Toledo, OH, USA
,
Sonia Masih1 Department of Urology, College of Medicine and Life Sciences, The University of Toledo, Toledo, OH, USA
,
Danae M Hamouda2 Department of Hematology Oncology, College of Medicine and Life Sciences, The University of Toledo, Toledo, OH, USA
&
Firas G Petros1 Department of Urology, College of Medicine and Life Sciences, The University of Toledo, Toledo, OH, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3062-0780
ORCID Icon
Pages 729-738 | Published online: 22 Feb 2022

References

  • NCCN. NCCN clinical practice guidelines in oncology (NCCN guidelines) for bladder cancer; 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed July 27, 2021.
  • Resch I, Shariat SF, Gust KM. PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer. Memo. 2018;11(1):43–46. doi:10.1007/s12254-018-0396-y
  • von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–3077. doi:10.1200/JCO.2000.18.17.3068
  • Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48–58.
  • Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
  • ClinicalTrials.gov; 2021. Available from: https://clinicaltrials.gov. Accessed September 12, 2021.
  • Apolo AB, Ellerton JA, Infante JR, et al. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN solid tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer. 2020;8:e001246. doi:10.1136/jitc-2020-001246
  • Garje R, Ginader T, Laux DE, et al. A phase Ib study of combination of avelumab and taxane-based chemotherapy in platinum refractory or ineligible metastatic urothelial cancer (AVETAX study). J Clin Oncol. 2020;38(6_suppl):487. doi:10.1200/JCO.2020.38.6_suppl.487
  • Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218–1230. doi:10.1056/NEJMoa2002788
  • Novakovic AM, Wilkins JJ, Dai H, et al. Changing body weight-based dosing to a flat dose for avelumab in metastatic Merkel cell and advanced urothelial carcinoma. Clin Pharmacol Ther. 2020;107(3):588–596. doi:10.1002/cpt.1645
  • Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7:278. doi:10.1186/s40425-019-0768-9
  • U.S. Food and Drug Administration. FDA approves avelumab for urothelial carcinoma maintenance treatment. Silver Spring (MD): U.S. Food and Drug Administration; 2020. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment. Accessed January 27, 2022.
  • Sonpavde G, Manitz J, Gao C, et al. Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors. J Urol. 2020;204(6):1173–1179. doi:10.1097/JU.0000000000001199

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.